問卷

TPIDB > Search Result

Search Result

篩選

List

7Cases

2025-11-01 - 2030-05-18

Phase III

Active
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
  • Condition/Disease

    Epithelial Ovarian Cancer

  • Test Drug

    注射用凍晶粉末 靜脈輸注液 輸注液 輸注液 濃縮粉劑 輸注液

Participate Sites
9Sites

Recruiting9Sites

2026-07-30 - 2031-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-07-01 - 2030-02-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2025-11-19 - 2030-06-30

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2022-05-01 - 2025-05-09

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-03-01 - 2030-03-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-07-01 - 2029-06-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites